Novo Nordisk's ambitious launch of Wegovy through a direct-to-consumer model could strain its finances as upfront marketing costs challenge profit timelines. While revenue forecasts for 2026 reflect high expectations driven by strong operational units, investors remain cautious about the potential delays in margin expansion linked to this costly strategy. Analysts recommend trimming long positions or adopting hedges amid this uncertain landscape.